In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Tomoyuki MinowaDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-8353-036X Sunita KeshariDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-4889-8430 Shan HeDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0009-0003-5844-4755 Akata SahaDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-3125-2871 Alexander S ShavkunovDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Josué E PinedaDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-8132-1804 Vakul MohantyDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-5536-6750 Sonali JindalJames P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-3911-6815 Ken ChenDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-4013-5279 Kenneth H HuDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-0294-0202 Linghua WangJames P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-9380-0266 Stephanie S WatowichDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-1969-659X Matthew M GubinDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-7443-2752 Funding
Project 3: Impact of tumor genetics on PDAC immunobiology and responses to macrophage-targeted immunotherapyP01CA244114 · NCI · STANFORD UNIVERSITY · PI ATTARDI, LAURA D, KIM, SEUNG K · 2021 to 2025
$10.0MStanford Tissue Mapping Center - STELLARU54HG012723 · NHGRI · STANFORD UNIVERSITY · PI PLEVRITIS, SYLVIA KATINA · 2022 to 2025
$7.8MCenter for Gastric Pre-Cancer Atlas of Multidimensional Evolution in 3D (GAME3D)U01CA294518 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Paul F Mansfield, Linghua Wang · 2024 to 2026
$5.4MPASSCODE (Pancreatic Adenocarcinoma Stromal Reprograming ConSortium COordination, Data Management and Education)U24CA274274 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI J. Jack LEE, ANIRBAN MAITRA · 2022 to 2026
$4.9MTumor cell lineage diversity and composition in gastric cancer progression and therapy resistanceR01CA266280 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Pawel K. Mazur, Linghua Wang · 2022 to 2026
$3.2MBhlhe40 Regulation of T Cell Function During Cancer ImmunotherapyR01CA282027 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Matthew M. Gubin · 2024 to 2026
$3.0MSystems analysis of mechanisms driving response to immunotherapy in clear cell cancersU01CA264611 · NCI · STANFORD UNIVERSITY · PI Andrew J. Gentles · 2022 to 2026
$2.7MSpatial and temporal tumor-immune co-evolution and interactions that model lung adenocarcinoma developmentU01CA264583 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Humam Kadara, Linghua Wang · 2022 to 2026
$2.1MNCI NIH HHS P01 CA244114NCI NIH HHS R01 CA266280NCI NIH HHS R01 CA282027NCI NIH HHS U01 CA264583NCI NIH HHS U01 CA264611NCI NIH HHS U01 CA294518NCI NIH HHS U24 CA274274NHGRI NIH HHS U54 HG012723
6 · The paper itselfAbstract
Dendritic cells (DCs) orchestrate anti-tumor immune responses, yet the full extent of their phenotypic diversity, and spatial dynamics within the tumor microenvironment (TME) remains incompletely understood. Here, we constructed an integrated atlas of tumor-infiltrating DCs by harmonizing single-cell transcriptomic data from 12 murine tumor studies and 28 published human cancer datasets, together with newly generated single-cell-resolved multiplexed tissue imaging across immunotherapy conditions in a murine model. We noted conserved transcriptional states across species, including canonical conventional type 1 DCs (cDC1s), diverse type 2 DC (cDC2) subpopulations, and two activation states characterized by CCR7 expression (CCR7
Identifiers
PMID41726948
PMCPMC12918938
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390